$ABT with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NYSE:ABT after a positive over reaction following its earnings release placing the stock in drift A with an expected accuracy of 50%.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.800 CHF
4.80 B CHF
33.77 B CHF
1.72 B
About Abbott Laboratories
Sector
Industry
CEO
Robert B. Ford
Website
Headquarters
Abbott Park
Founded
1888
FIGI
BBG006M6Y1D4
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Abbott Laboratories | Chart & Forecast SummaryOn The 15 Minutes Chart You Can See
# A Trend | A Time Frame Conductive
- This Measurement on Session Means;
* Support & Resistance | HH & HL's
and also a
* Trade Area | Focus & Motion Ahead
Containing A Falling Wedge That Acts Like Support On The Valid Target Dotted Through The Arrow Confir
Abbott Labs Shakes Off Downtrend, Sets Sights on $142 milestoneIn December 2021, the stock price hit an all-time high near the 142 mark, after which it experienced a significant drop.
Following this decline, the price found support around the 90 level and began to recover.
Last week, the stock managed to break through the upper boundary of the descending para
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought the dip on ABT:
Now analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week,
I would consider purchasing the 115usd strike price Puts with
an expiration date of 2024-10-18,
for a premium of approximately $1.35.
If t
ABTan upward trend in the prices of an industry's stocks or the overall rise in broad market indices, characterized by high investor confidence
Abbott Laboratories | ABT | Long at $110.00Abbott Laboratories NYSE:ABT has been making higher highs and lower lows over the last year, potentially signaling a reversal in its downward trend. Monkeypox and the return of cold/flu/COVID season may spark another run to close the price gap on the daily chart around $140. It is currently in a p
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bough the dip on ABT:
Now analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week,
I would consider purchasing the 105usd strike price Calls with
an expiration date of 2024-8-16,
for a premium of approximately $2.19.
If th
Daily Short @120Supply area between 120 and 122 at daily. This area is nested within monthly and weekly supply are.
Note that this area is not fresh as this rea is tested one time with strong impulse. Since the freshness is lost this area may not work.
ABT Long Trade IdeaI´m considering that we will have another leg as a correction to the upside.
My entry is at 104.21 (50% pullback), with first target in the recent high (108.70), and final target at 113.06 (2x risk).
ABT updateThis is a trade I did enter after my initial post, I was bullish on ABT turning around, and hoping for falling interest rates which did occur. My strategy here was to purchase a LEAP before this breakout. I will hold this and sell covered-calls against it after earnings next week, if we get a large
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where ABL is featured.
Frequently Asked Questions
The current price of ABL is 103.892 CHF — it has increased by 3.05% in the past 24 hours. Watch ABBOTT LABS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ABBOTT LABS stocks are traded under the ticker ABL.
ABL stock has risen by 3.00% compared to the previous week, the month change is a 4.44% rise, over the last year ABBOTT LABS has showed a 16.71% increase.
We've gathered analysts' opinions on ABBOTT LABS future price: according to them, ABL price has a max estimate of 129.63 CHF and a min estimate of 101.79 CHF. Watch ABL chart and read a more detailed ABBOTT LABS stock forecast: see what analysts think of ABBOTT LABS and suggest that you do with its stocks.
ABL stock is 2.96% volatile and has beta coefficient of 0.11. Track ABBOTT LABS stock price on the chart and check out the list of the most volatile stocks — is ABBOTT LABS there?
Today ABBOTT LABS has the market capitalization of 179.68 B, it has increased by 0.26% over the last week.
Yes, you can track ABBOTT LABS financials in yearly and quarterly reports right on TradingView.
ABBOTT LABS is going to release the next earnings report on Jan 22, 2025. Keep track of upcoming events with our Earnings Calendar.
ABL earnings for the last quarter are 1.03 CHF per share, whereas the estimation was 1.02 CHF resulting in a 0.65% surprise. The estimated earnings for the next quarter are 1.19 CHF per share. See more details about ABBOTT LABS earnings.
ABBOTT LABS revenue for the last quarter amounts to 9.01 B CHF, despite the estimated figure of 8.94 B CHF. In the next quarter, revenue is expected to reach 9.76 B CHF.
ABL net income for the last quarter is 1.39 B CHF, while the quarter before that showed 1.17 B CHF of net income which accounts for 19.19% change. Track more ABBOTT LABS financial stats to get the full picture.
Yes, ABL dividends are paid quarterly. The last dividend per share was 0.47 CHF. As of today, Dividend Yield (TTM)% is 1.88%. Tracking ABBOTT LABS dividends might help you take more informed decisions.
ABBOTT LABS dividend yield was 1.89% in 2023, and payout ratio reached 63.81%. The year before the numbers were 1.75% and 49.05% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 21, 2024, the company has 114.00 K employees. See our rating of the largest employees — is ABBOTT LABS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABBOTT LABS EBITDA is 8.45 B CHF, and current EBITDA margin is 24.13%. See more stats in ABBOTT LABS financial statements.
Like other stocks, ABL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABBOTT LABS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABBOTT LABS technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABBOTT LABS stock shows the strong buy signal. See more of ABBOTT LABS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.